Prophylactic ECMO Support during Elective Coronary Percutaneous Interventions in High-Risk Patients: A Single-Center Experience.


Journal

Journal of interventional cardiology
ISSN: 1540-8183
Titre abrégé: J Interv Cardiol
Pays: United States
ID NLM: 8907826

Informations de publication

Date de publication:
2023
Historique:
received: 06 07 2022
revised: 17 10 2022
accepted: 25 11 2022
entrez: 16 2 2023
pubmed: 17 2 2023
medline: 18 2 2023
Statut: epublish

Résumé

Evidence regarding the impact of prophylactic implantation of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for elective high-risk percutaneous coronary intervention (PCI) is limited. The purpose of this paper is to evaluate the outcome during index hospitalization and 3 years after interventions. This is an observational retrospective study including all patients undergoing elective, high-risk PCI and receiving VA-ECMO for cardiopulmonary support. Primary endpoints were in-hospital and 3- year major adverse cardiovascular and cerebrovascular event (MACCE) rates. Secondary endpoints were vascular complications, bleeding, and procedural success. Nine patients were included in total. All patients were considered inoperable by the local heart team, and 1 patient had a previous coronary artery bypass graft (CABG). All patients were hospitalized for an acute heart failure episode 30 days before the index procedure. Severe left ventricular dysfunction was present in 8 patients. The main target vessel was the left main coronary artery in 5 cases. Complex PCI techniques were used: bifurcations with 2 stents in 8 patients, rotational atherectomy was performed in 3, and coronary lithoplasty in 1 case. PCI was successful in all of the patients with revascularization of all target and additional lesions. Eight of the 9 patients survived for at least 30 days after the procedure, and 7 patients survived for 3 years after the procedure. Regarding the complication rate, 2 patients suffered from limb ischemia and were treated by an antegrade perfusion, 1 patient had a femoral perforation that needed surgical repair, 6 patients had a hematoma, 5 patients had a significant drop in hemoglobin of more than 2 g/dl and received blood transfusions, 2 patients were treated for septicemia, and 2 patients needed hemodialysis. Prophylactic use of VA-ECMO in elective patients is an acceptable strategy for revascularization by high-risk coronary percutaneous interventions with good long-term outcomes for patients considered inoperable when a clear clinical benefit is expected. Regarding the potential risk of complications due to a VA-ECMO system, the selection of candidates in our series was based on a multiparameter analysis. The two main triggers in favor of prophylactic VA-ECMO in our studies were the presence of a recent heart failure episode and the high probability of periprocedural prolonged impairment of the coronary flow through the major epicardial artery.

Identifiants

pubmed: 36793669
doi: 10.1155/2023/5332038
pmc: PMC9922177
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5332038

Informations de copyright

Copyright © 2023 Claudiu Ungureanu et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Heart Fail Rev. 2020 Sep;25(5):833-846
pubmed: 31677013
J Cardiothorac Vasc Anesth. 2018 Jun;32(3):1507-1524
pubmed: 29126678
Crit Care Med. 2010 Jan;38(1):152-60
pubmed: 19770739
J Card Fail. 2015 Jun;21(6):499-518
pubmed: 26036425
J Am Coll Cardiol. 2015 May 19;65(19):e7-e26
pubmed: 25861963
Int J Cardiol. 2016 Nov 15;223:412-417
pubmed: 27544596
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Cardiovasc Revasc Med. 2021 Nov;32:63-67
pubmed: 33358182
J Invasive Cardiol. 2016 Jun;28(6):243-5
pubmed: 27236008
Circulation. 2012 Oct 2;126(14):1717-27
pubmed: 22935569
Neth Heart J. 2020 Mar;28(3):139-144
pubmed: 31782108
JACC Cardiovasc Interv. 2015 Feb;8(2):229-244
pubmed: 25700745
N Engl J Med. 2009 Mar 5;360(10):961-72
pubmed: 19228612
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Circ J. 2016;80(3):572-8
pubmed: 26853720
Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):283-91
pubmed: 24336784
JACC Cardiovasc Interv. 2016 May 9;9(9):871-83
pubmed: 27151604
J Invasive Cardiol. 2018 Dec;30(12):456-460
pubmed: 30504514
Curr Cardiol Rep. 2014 Dec;16(12):544
pubmed: 25326728

Auteurs

Claudiu Ungureanu (C)

Cardiovascular Department, Jolimont Hospital, La Louvière, Belgium.

Marc Blaimont (M)

Cardiovascular Department, Jolimont Hospital, La Louvière, Belgium.

Hugues Trine (H)

Intensive Care Department, Jolimont Hospital, La Louvière, Belgium.

Pierre Henin (P)

Intensive Care Department, Jolimont Hospital, La Louvière, Belgium.

Romain Courcelle (R)

Intensive Care Department, Jolimont Hospital, La Louvière, Belgium.

Yves Laurent (Y)

Intensive Care Department, Jolimont Hospital, La Louvière, Belgium.

Patrick Van Ruyssevelt (P)

Cardiothoracic Surgery Department, Jolimont Hospital, La Louvière, Belgium.

Caroline Lepièce (C)

Cardiovascular Department, Jolimont Hospital, La Louvière, Belgium.

Vincent Huberlant (V)

Intensive Care Department, Jolimont Hospital, La Louvière, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH